A Quantitative Exploration of Surface Antigen Expression in Common B-Cell Malignancies Using Flow Cytometry

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Immunological Investigations

• Publication date

  2006-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/08820130500496878PMID 16531332
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody

  2005cited by this paper
• Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19

  2005cited by this paper
• Formalization of the MESF unit of fluorescence intensity

  2004cited by this paper
• 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.

  2003cited by this paper
• Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia

  2003cited by this paper
• Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro.

  2003cited by this paper
• Rituximab in relapsed or refractory hairy cell leukemia.

  2003cited by this paper
• Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs.

  2002cited by this paper
• Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia.

  2001cited by this paper
• Multiparameter data acquisition and analysis of leukocytes by flow cytometry.

  2001cited by this paper
• Autoimmunity in chronic lymphocytic leukemia

  2001cited by this paper
• Rituximab, a chimaeric anti‐CD20 monoclonal antibody, in the treatment of hairy cell leukaemia

  2001cited by this paper
• Cell preparation for the identification of leukocytes.

  2001cited by this paper
• Quantitative flow cytometry for the differential diagnosis of leukemic B‐cell chronic lymphoproliferative disorders

  2000cited by this paper
• Quantitative expression of CD23 and its ligand CD21 in chronic lymphocytic leukemia.

  2000cited by this paper
• Monoclonal antibody treatment of solid tumors: a coming of age.

  2000cited by this paper
• The cancer anorexia-cachexia syndrome.

  2000cited by this paper
• B-cell chronic lymphocytic leukemia: a bird of a different feather.

  1999cited by this paper
• Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders.

  1999cited by this paper
• IDEC‐C2B8 anti‐CD20 (Rituximab) immunotherapy in patients with low‐grade non‐Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients

  1999cited by this paper
• Performance of calibration standards for antigen quantitation with flow cytometry.

  1998cited by this paper
• Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

  1998cited by this paper
• Quantitative fluorescence flow cytometry: a comparison of the three techniques for direct and indirect immunofluorescence.

  1998cited by this paper
• Clinico‐prognostic relevance of quantitative immunophenotyping in B‐cell chronic lymphocytic leukemia with emphasis on the expression of CD20 antigen and surface immunoglobulins

  1998cited by this paper
• Levels of expression of CD19 and CD20 in chronic B cell leukaemias.

  1998cited by this paper
• Determination of CD4 antigen density on cells: role of antibody valency, avidity, clones, and conjugation.

  1998cited by this paper
• Flow cytometric quantitation of immunofluorescence intensity: problems and perspectives. European Working Group on Clinical Cell Analysis.

  1998cited by this paper
• Terminology and nomenclature for standardization in quantitative fluorescence cytometry.

  1998cited by this paper
• U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: selection of antibody combinations.

  1997cited by this paper
• Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy

  1997cited by this paper
• Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy.

  1997cited by this paper
• IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

  1997cited by this paper
• Standardizing flow cytometry: construction of a standardized fluorescence calibration plot using matching spectral calibrators.

  1996cited by this paper
• Quantitative determination of the MDR-related P-glycoprotein, Pgp 170, by a rapid flow cytometric technique.

  1996cited by this paper
• Constitutive endocytosis and degradation of CD22 by human B cells.

  1995cited by this paper
• Quantitative flow cytometry can distinguish between normal and leukaemic B‐cell precursors

  1995cited by this paper
• A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

  1994cited by this paper
• Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

  1994cited by this paper
• Cell preparation for the identification of leukocytes.

  1994cited by this paper
• Retention of B-cell-specific monoclonal antibodies by human lymphoma cells.

  1994cited by this paper
• Cell preparation for the identification of leukocytes.

  1990cited by this paper
• CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire.

  1989cited by this paper
• Cytofluorometric quantification of cell-surface antigens by indirect immunofluorescence using monoclonal antibodies.

  1985cited by this paper
• Antisera to acute lymphoblastic leukemia cells.

  1975cited by this paper

• Beyond R-CHOP: The rise of antibody-drug conjugates in DLBCL.

  2026cites this paper
• Flow Cytometry for B-Cell Non-Hodgkin and Hodgkin Lymphomas

  2025cites this paper
• CAR-NK cells for haematological cancers.

  2025cites this paper
• Second Generation Tiancimycin-Based Antibody–Drug Conjugates Enabled by Highly Efficient Semi-synthetic Approach Specifically Targeting B-Cell Malignancies

  2025cites this paper
• A Quantitative Microfluidic Flow Cytometer Based on Spaced Uniform Optical Field

  2025cites this paper
• Clinically approved immunotoxins targeting hematological cancers: “the best of both worlds”

  2025cites this paper
• Limitations of CAR-T-Cell Therapy in Hematologic Malignancies: Focusing on Antigen Escape and T-Cell Dysfunction

  2025cites this paper
• Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR/Cas9

  2024cites this paper
• Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review

  2024cites this paper
• Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions

  2024cites this paper
• Advancements in the design and function of bispecific CAR-T cells targeting B Cell-Associated tumor antigens.

  2024cites this paper
• Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma

  2024cites this paper
• Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trial

  2024cites this paper
• Therapeutic approaches to enhance natural killer cell cytotoxicity

  2024cites this paper
• Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas

  2024cites this paper
• Heterogeneous Surface CD79b Expression in Aggressive B-Cell Lymphomas Assessed by Flow Cytometry on Lymph Node Biopsies

  2024cites this paper
• Alternative splicing of its 5’-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

  2023cites this paper
• Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

  2023cites this paper
• Targeting CD22 for B-cell hematologic malignancies

  2023cites this paper
• Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment

  2023cites this paper
• Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

  2023cites this paper
• The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

  2023cites this paper
• Chimeric Antigen Receptor CAR-T Therapy on the Move: Current Applications and Future Possibilities

  2023cites this paper
• Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions

  2023cites this paper
• Monoclonal Antibodies in Oncology: A Decade of Novel Options

  2023cites this paper
• CD20, generalidades básicas-moleculares y su posible relación como marcador de mal pronóstico en leucemia

  2023cites this paper
• Multi-targeted immunotherapeutics to treat B cell malignancies.

  2023cites this paper
• Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR

  2023cites this paper
• Spatial metabolomics reveal mechanisms of dexamethasone against pediatric pneumonia.

  2023cites this paper
• Antibody–drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry

  2023cites this paper
• Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies

  2023cites this paper
• ROR1: an orphan becomes apparent

  2022cites this paper
• New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma

  2022cites this paper
• Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy

  2022influential citation
• Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy

  2022cites this paper
• CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

  2022cites this paper
• A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?

  2022influential citation
• Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma

  2022cites this paper
• The journey of CAR-T therapy in hematological malignancies

  2022cites this paper
• CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19.

  2022cites this paper
• CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis

  2022cites this paper
• Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity

  2022cites this paper
• Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma

  2022cites this paper
• Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults

  2021cites this paper
• Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies

  2021cites this paper
• Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma

  2021cites this paper
• The clinical development of antibody–drug conjugates — lessons from leukaemia

  2021cites this paper
• Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.

  2021cites this paper
• Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy

  2021cites this paper
• CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

  2021cites this paper
• OTT_A_312904 4023..4037

  2021cites this paper
• CAR T-cell therapy for B-cell lymphoma.

  2021cites this paper
• New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL

  2021cites this paper
• The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  2021cites this paper
• CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles

  2021cites this paper
• Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma

  2021cites this paper
• Targeting CD33 for acute myeloid leukemia therapy

  2021cites this paper
• The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy

  2020cites this paper
• Epigenetic-mediated apoptosis in aggressive B-cell lymphomas

  2020cites this paper
• Antibody–drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin

  2020cites this paper
• Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles

  2020cites this paper
• Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.

  2020cites this paper
• Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma

  2020cites this paper
• Significance of CD10 protein expression in the diagnostics of follicular lymphoma: A comparison of conventional immunohistochemistry with flow cytometry supported by the establishment of BCL2 and BCL6 rearrangements

  2020cites this paper
• HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma

  2020cites this paper
• TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens

  2020cites this paper
• Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naïve B-cell lymphoma treated with a 19-week CHOP protocol.

  2019cites this paper
• Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.

  2019cites this paper
• Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia

  2019cites this paper
• Updates on CAR T‐cell therapy in B‐cell malignancies

  2019cites this paper
• Single-Cell Protein Assays: A Review.

  2018cites this paper
• Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

  2018influential citation
• Studies of Bruton’s tyrosine kinase inhibitors in B-cell malignancies

  2018cites this paper
• Development of a novel T cell engaging antibody derivative for local PD-1/PD-L1 immune checkpoint blockade in acute myeloid leukemia

  2018cites this paper
• Tumor target amplification: Implications for nano drug delivery systems

  2018cites this paper
• Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.

  2018cites this paper
• Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells

  2018cites this paper
• Computational Systems Biology

  2018cites this paper
• Calicheamicin Antibody-Drug Conjugates for Liquid and Solid Tumor Indications

  2017cites this paper
• Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence

  2017cites this paper
• Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results

  2017cites this paper
• Combination therapy with the type II anti-CD20 antibody obinutuzumab

  2017cites this paper
• SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells

  2017cites this paper
• CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL

  2017cites this paper
• Chemical Assembly of Antibody-Drug Conjugates

  2017cites this paper
• Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.

  2016cites this paper
• CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells

  2016cites this paper
• Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls

  2016cites this paper
• Sentinel Lymph Node in Breast Cancer: Review Article from a Pathologist’s Point of View

  2016cites this paper
• Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma

  2016cites this paper
• Novel Immunotherapies for Hematological Malignancies.

  2016cites this paper
• Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells

  2016cites this paper
• Immunotherapy for B-acute Lymphoblastic Leukemia by Focusing on Monoclonal Antibody and CAR- T-cell Application

  2016cites this paper
• Résistances/sensibilisations aux anti-CD20 (rituximab) dans les lymphomes diffus à grandes cellules B (DLBCL)

  2016cites this paper
• Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

  2015cites this paper
• Expression of MUM1, CD30, CD15 and CD20 by neoplastic cells of Lymphomas

  2015cites this paper
• Antibody-targeted drugs and drug resistance--challenges and solutions.

  2015cites this paper
• Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b.

  2015cites this paper
• Clinical features and diagnosis of hairy cell leukemia.

  2015cites this paper
• Utility of CD200 expression and CD20 antibody binding capacity in differentiating chronic lymphocytic leukemia from other chronic lymphoproliferative disorders

  2015influential citation